|
Published by: Millennium Research
Published: Dec. 1, 2005
Table of Contents
- EXECUTIVE SUMMARY
- METHODOLOGY
- 1.0 ORTHOPEDIC BIOMATERIALS BACKGROUND
- 1.1 Bone Graft Overview
- 1.1.2 Autograft
- 1.1.3 Allograft
- 1.1.4 Demineralized Bone Matrix
- 1.1.5 Synthetic Bone
- 1.1.6 Growth Factors
- 1.2 Hyaluronic Acid Viscosupplementation Overview
- 1.2.1 Hyaluronic Acid Viscosupplementation Reimbursement
- 1.3 Osteoarthritis Overview
- 1.3.1 Causal Factors
- 1.3.2 Incidence
- 1.3.3 Treatment Alternatives to Hyaluronic Acid Viscosupplementation
- 1.3.3.1 Nonpharmacologic Treatments
- 1.3.3.2 Pharmacologic Treatments
- 1.4 Machined Bone Interbody Devices Overview
- 1.5 Cartilage Repair Overview
- 1.5.1 Osteoarticular Autografts
- 1.5.2 Osteoarticular Allografts
- 1.5.3 Autologous Chondrocyte Implantation
- 1.6 Platelet Concentration System Overview
- 2.0 MARKET OVERVIEW
- 2.1 Market Overview
- 2.2 Market Analysis
- 2.2.1 Procedures
- 2.2.2 Market Forecast
- 2.3 Competitive Analysis
- 3.0 BONE GRAFT SUBSTITUTES
- 3.1 Market Overview
- 3.2 Market Analysis
- 3.2.1 Procedures
- 3.2.2 Segmentation by Material
- 3.2.2.1 Autograft
- 3.2.2.2 NP Allograft
- 3.2.2.3 Demineralized Bone Matrix
- 3.2.2.4 Synthetic
- 3.2.2.5 Growth Factors
- 3.2.3 Segmentation by Application
- 3.2.4 Market Drivers and Limiters
- 3.2.4.2 Market Drivers
- 3.2.4.3 Market Limiters
- 3.2.5 Market Forecast
- 3.3 Spinal Fusion Market Overview
- 3.3.2 Thoracolumbar Fusion Market
- 3.3.3 Cervical Fusion Market
- 3.4 Trauma Application Market Overview
- 3.4.2 Fresh Fracture Market
- 3.4.3 Nonunion Fracture Market
- 3.5 Reconstructive Surgery Market Overview
- 3.5.2 Revision Hip Market
- 3.5.3 Revision Knee Market
- 3.5.4 Primary Knee Market
- 3.5.5 Primary Hip Market
- 3.6 Craniomaxillofacial Application Market Overview
- 3.7 Competitive Analysis
- 3.7.1 Trends and Issues
- 3.7.2 Leading Competitors
- 3.8 Products in Development
- 3.8.1 Small Peptides
- 3.8.1.1 P-15
- 3.8.1.2 Peptos
- 3.8.1.3 Chrysalin
- 3.8.1.4 B2A2
- 3.8.1.5 AC-100
- 3.8.2 GFs
- 3.8.2.1 GEM 21S
- 3.8.2.2 LIM Mineralization Protein-1
- 3.8.2.3 rhGDF-5 (formerly known as MP52)
- 3.8.2.4 PuraMatrix
- 3.8.2.5 BST-GEL
- 3.8.2.6 Ossigel
- 3.8.3 Stem Cells
- 4.0 HYALURONIC ACID VISCOSUPPLEMENTATION
- 4.1 Market Overview
- 4.2 Market Analysis
- 4.2.1 Procedures
- Total Injection Volumes
- 4.2.2 Hyaluronic Acid Treatment Market
- 4.2.3 Market Drivers and Limiters
- 4.2.3.2 Market Drivers
- 4.2.3.3 Market Limiters
- 4.2.4 Market Forecast
- 4.2.4.2 3-injection Hyaluronic Acid Market
- 4.2.4.3 5-injection HA Market
- 4.3 Competitive Analysis
- 4.3.1 Leading Competitors
- 4.3.2 Emerging Competitors
- 5.0 MACHINED BONE INTERBODY DEVICES
- 5.1 Market Overview
- 5.2 Market Analysis
- 5.2.1 Market Drivers and Limiters
- 5.2.1.2 Market Drivers
- 5.2.1.3 Market Limiters
- 5.2.2 Market Forecast
- 5.3 Competitive Analysis
- 6.0 CARTILAGE REPAIR
- 6.1 Market Overview
- 6.2 Market Analysis
- 6.2.2 Procedures
- 6.2.2.1 ACI Market
- 6.2.2.2 OA Market
- 6.2.3 Market Forecast
- 6.2.4 Market Drivers and Limiters
- 6.2.4.2 Market Drivers
- 6.2.4.3 Market Limiters
- 6.3 Competitive Analysis
- 6.3.1 Leading Competitors
- 6.3.2 Emerging Competitors
- 7.0 PLATELET CONCENTRATION SYSTEMS
- 7.1 Market Overview
- 7.2 Market Analysis
- 7.2.2 Market Drivers and Limiters
- 7.2.2.2 Market Drivers
- 7.2.2.3 Market Limiters
- 7.3 Competitive Analysis
- 7.3.1 Leading Competitors
- APPENDIX A: LIST OF ABBREVIATIONS
- List of Exhibits
- Executive Summary
- Exhibit ES-1: Orthopedic Biomaterials Market, US (US$), 2004-2010
- Exhibit ES-2: BGS Market, US (US$), 2004-2010
- Exhibit ES-3: HA Viscosupplementation Market, US (US$), 2004-2010
- Exhibit ES-4: Machined Bone IBD Market, by Segment, US, 2005
- Exhibit ES-5: Cartilage Repair Market, US (US$), 2004-2010
- Chapter 1: Orthopedic Biomaterials Background Exhibit 1-1: Characteristics of BGS Materials
- Exhibit 1-2: Advantages and Disadvantages of Various BGS Materials
- Exhibit 1-3: Selected Synthetic BGS Materials
- Chapter 2: Market Overview
- Exhibit 2-1: Orthopedic Biomaterials Market, by Segment, US, 2005
- Exhibit 2-2: Orthopedic Biomaterials Market, by Device, US (US$), 2004-2010
- Exhibit 2-3: Leading Competitors in the US Orthopedic Biomaterials Market, by Device, 2005
- Chapter 3: Bone Graft Substitutes
- Exhibit 3-1: BGS Market, by Material, US (US$), 2004-2010 (Graphical Format)
- Exhibit 3-2: BGS Procedures, US, 2004-2010
- Exhibit 3-3: BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-4: BGS Procedures, by Material, As a % of Total, US, 2004-2010
- Exhibit 3-5: BGS Procedures, by Application, US, 2004-2010
- Exhibit 3-6: BGS Procedures, by Indication, As a % of Total, US, 2004-2010
- Exhibit 3-7: Drivers and Limiters of the BGS Market, US, 2005
- Exhibit 3-8: BGS Market, by Material, US (US$), 2004-2010 (Tabular Format)
- Exhibit 3-9: BGS Market, by Indication, US (US$), 2004-2010
- Exhibit 3-10: Spine BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-11: Spine BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-12: Thoracolumbar Spine BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-13: One-Level Thoracolumbar Spine BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-14: Two-Level Thoracolumbar Spine BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-15: Multilevel Thoracolumbar Spine BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-16: Thoracolumbar Spine BGS ASPs, by Material, US (US$), 2004-2010
- Exhibit 3-17: One-Level Thoracolumbar Spine BGS ASPs by Material, US (US$), 2004-2010
- Exhibit 3-18: Two-Level Thoracolumbar Spine BGS ASPs, by Material, US (US$), 2004-2010
- Exhibit 3-19: Multilevel Thoracolumbar Spine BGS ASPs, by Material, US (US$), 2004-2010
- Exhibit 3-20: Thoracolumbar Spine BGS Market, by Material, US (US$), 2004- 2010
- Exhibit 3-21: One-Level Thoracolumbar Spine BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-22: Two-Level Thoracolumbar Spine BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-23: Multilevel Thoracolumbar Spine BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-24: Cervical Spine BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-25: One-Level Cervical Spine BGS Procedures, by Material, US, 2004- 2010
- Exhibit 3-26: Two-Level Cervical Spine BGS Procedures, by Material, US, 2004- 2010
- Exhibit 3-27: Multilevel Cervical Spine BGS Procedures, by Material, US, 2004- 2010
- Exhibit 3-28: Cervical Spine BGS ASPs, by Material, US (US$), 2004-2010
- Exhibit 3-29: One-Level Cervical Spine BGS ASPs, by Material, US (US$), 2004- 2010
- Exhibit 3-30: Two-Level Cervical Spine BGS ASPs, by Material, US (US$), 2004- 2010
- Exhibit 3-31: Multilevel Cervical Spine BGS ASPs, by Material, US (US$), 2004- 2010
- Exhibit 3-32: Cervical Spine BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-33: One-Level Cervical Spine BGS Market, by Material, US (US$), 2004- 2010
- Exhibit 3-34: Two-Level Cervical Spine BGS Market, by Material, US (US$), 2004- 2010
- Exhibit 3-35: Multilevel Cervical Spine BGS Market, by Material, US (US$), 2004- 2010
- Exhibit 3-36: Trauma BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-37: Trauma BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-38: Fresh Fracture Procedures, by Type, US, 2004-2010
- Exhibit 3-39: Fresh Fracture Procedures Using BGS Material, US, 2004-2010
- Exhibit 3-40: Fresh Fracture BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-41: Fresh Fracture BGS ASPs, by Material, US (US$), 2004-2010
- Exhibit 3-42: Fresh Fracture BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-43: Nonunion Fracture Procedures Using BGS Material, US, 2004-2010
- Exhibit 3-44: Nonunion Fracture BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-45: Nonunion Fracture BGS ASPs, by Material, US (US$), 2004-2010
- Exhibit 3-46: Nonunion Fracture BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-47: Reconstructive BGS Procedures, by Indication, US, 2004-2010
- Exhibit 3-48: Reconstructive BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-49: Reconstructive BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-50: Revision Hip BGS Penetration, US, 2004-2010
- Exhibit 3-51: Revision Hip BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-52: Revision Hip BGS ASPs per Procedure, by Material, US (US$), 2004- 2010
- Exhibit 3-53: Revision Hip BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-54: Revision Knee BGS Penetration, US, 2004-2010
- Exhibit 3-55: Revision Knee BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-56: Revision Knee BGS ASP per Procedure, by Material, US (US$), 2004- 2010
- Exhibit 3-57: Revision Knee BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-58: Primary Knee BGS Penetration, US, 2004-2010
- Exhibit 3-59: Primary Knee BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-60: Primary Knee BGS ASPs per Procedure, by Material, US (US$), 2004- 2010
- Exhibit 3-61: Primary Knee BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-62: Primary Hip BGS Penetration, US, 2004-2010
- Exhibit 3-63: Primary Hip BGS Procedures, by Material, US, 2004-2010
- Exhibit 3-64: Primary Hip BGS ASPs per Procedure, by Material, US (US$), 2004- 2010
- Exhibit 3-65: Primary Hip BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-66: CMF BGS Procedures, by Material, 2004-2010
- Exhibit 3-67: CMF BGS ASPs per Procedure, by Material, US (US$), 2004-2010
- Exhibit 3-68: CMF BGS Market, by Material, US (US$), 2004-2010
- Exhibit 3-69: Leading Competitors in the BGS Market, by Segment, 2005
- Chapter 4: Hyaluronic Acid Viscosupplementation
- Exhibit 4-1: HA Treatment Market, US (US$), 2004-2010 (Graphical Format)
- Exhibit 4-2: HA Procedure Segmentation, by Number of Injections, US, 2005
- Exhibit 4-3: HA Injections, by Type, US, 2004-2010
- Exhibit 4-4: HA Treatments, by Type, US, 2004-2010
- Exhibit 4-5: HA Treatment Volumes, US, 2004-2010
- Exhibit 4-6: Drivers and Limiters of the HA Market, US
- Exhibit 4-7: HA Injection Market, US (US$), 2004-2010
- Exhibit 4-8: HA Injection Market, by Indication, US, 2004-2010
- Exhibit 4-9: HA Treatment Market, US (US$), 2004-2010
- Exhibit 4-10: HA Treatments, by Indication, US, 2004-2010
- Exhibit 4-11: 3-Injection HA Injection Volumes, US, 2004-2010
- Exhibit 4-12: 3-Injection HA Injection Market, US (US$), 2004-2010
- Exhibit 4-13: 3-Injection HA Injection, by Indication, US, 2004-2010
- Exhibit 4-14: 3-Injection HA Treatment Market, US (US$), 2004-2010
- Exhibit 4-15: 3-Injection HA Treatment, by Indication, US, 2004-2010
- Exhibit 4-16: 5-Injection HA Treatment Volumes, US, 2004-2010
- Exhibit 4-17: 5-injection HA Injection Market, US (US$), 2004-2010
- Exhibit 4-18: 5-injection HA Injection Market, by Indication, US (US$), 2004-2010
- Exhibit 4-19: 5-injection HA Treatment Market, US (US$), 2004-2010
- Exhibit 4-20: 5-injection HA Treatment Market, by Indication, US, 2004-2010
- Exhibit 4-21: Leading Competitors in the HA Viscosupplementation Market, US, 2005
- Chapter 5: Machined Bone Interbody Devices
- Exhibit 5-1: Machined Bone IBD Market, US (US$), 2004-2010
- Exhibit 5-2: Drivers and Limiters of the Machined Bone IBD Market, US
- Exhibit 5-3: Over-65 cohort, US, 2000-2050
- Exhibit 5-4: Machined Bone IBD Market, by Approach, US (US$), 2005
- Exhibit 5-5: Machined Bone IBD Market, by Approach, US (US$), 2004-2010
- Exhibit 5-6: Machined Bone IBD Market Growth, by Device, US, 2005-2010
- Exhibit 5-7: Machined Bone Devices per Procedure, US, 2004-2010
- Exhibit 5-8: Leading Competitors of the Machined Bone IBD Market, US, 2005
- Chapter 6: Cartilage Repair
- Exhibit 6-1: Cartilage Repair Market, by Segment, US (US$), 2004-2010 (Graphical Format)
- Exhibit 6-2: Cartilage Repair Market, by Segment, US (US$), 2004-2010 (Tabular Format)
- Exhibit 6-3: ACI Market, US (US$), 2004-2010
- Exhibit 6-4: OA Allograft Market, US (US$), 2004-2010
- Exhibit 6-5: Drivers and Limiters of the Cartilage Repair Market, US
- Exhibit 6-6: Leading Competitors in the Cartilage Repair Market, by Segment, US, 2005
- Chapter 7: Platelet Concentration Systems
- Exhibit 7-1: PCS Market, US (US$), 2004-2010 (Graphical Format)
- Exhibit 7-2: PCS Market, US (US$), 2004-2010 (Tabular Format)
- Exhibit 7-3: PCS Procedures, by Indication, US, 2004-2010
- Exhibit 7-4: Drivers and Limiters of the PCS Market, US
- Exhibit 7-5: Leading Competitors in the PCS Market, US, 2005
AbstractThis market reached a value of over $1.7 billion in 2005 and will grow consistently over the next five years.
The US market for orthopedic biomaterials is comprised of Bone graft substitutes (BGS), Spinal machined bone, Osteoarticular allografts, Hyaluronic acid (HA) viscosupplementation, Emerging growth factor (GF) technologies, Platelet concentration systems (PCS) and Autologous chondrocyte implantation (ACI).
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
